Moving towards an improved microsimulation model of the Australian pharmaceutical benefits scheme

Australian Economic Review

Volumn 37, Issue 1, 2004, Pages 41-61

  Brown, Laurie ^a   Abello, Annie ^a   Phillips, Ben ^a   Harding, Ann ^a  

^a UNIVERSITY OF CANBERRA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH EXPENDITURE;

EID: 2042460865     PISSN: 00049018     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-8462.2004.00307.x     Document Type: Article

References (44)

1. Australian Bureau of Statistics 2001, Government Benefits, Taxes and Household Income, Australia, Cat. no. 6537.0, ABS, Canberra.
2. Birkett, D. J., Mitchell, A. S. and McManus, P. 2001, 'A cost-effectiveness approach to drug subsidy and pricing in Australia', Health Affairs, vol. 20, no. 3, pp. 104-14.
3. Brennecke, R. 1981, Bevolkerungsentwicklung, Gesundheitsbeschwerden und Inanspruchnahme von Arzten, Sfb 3-Arbeitspapier no. 52 (Sonderforchungsbereich 3, Mikroanalytische Grundlagen der Gesellschaftspolitik: Frankfurt/M., Mannheim).
4. Brown, L. J. and Harding, A. 2002, 'Social modelling and public policy: Application of microsimulation modelling in Australia', Journal of Artificial Societies and Social Simulation, vol. 5, no. 4, .
5. Brown, L. J., Walker, A., Waters, A., Harding, A. and Thurecht, L. 2002, Funding of High Cost Biotechnology and Other Innovative Targeted Therapies under the Pharmaceutical Benefits Scheme, Refereed Position Paper, National Centre for Social and Economic Modelling, Canberra.
6. Commonwealth of Australia 2002a, Budget Strategy and Outlook 2002-03, Budget Paper no. 1, Treasury, Commonwealth of Australia.
7. Commonwealth of Australia 2002b, Intergenerational Report 2002-03, Budget Paper no. 5, Treasury, Commonwealth of Australia.
8. Commonwealth Department of Health and Ageing 2003, Australian Statistics on Medicines, 1999-2000, Commonwealth of Australia, Canberra.
9. Cookson, R. 2000, ASTEC Non-EU Case Study on Australia, London School of Economics and Political Science, London, .
10. Creedy, J. 2001, 'Tax modelling', Economic Record, vol. 77, pp. 189-202.
11. Dalton, A. 2001, 'Australia's pharmaceutical benefits system: Flawed but improving, and better than anywhere else', Australian Health Review, vol. 24, no. 2, pp. 7-14.
12. Donovan, J. 2002, 'The benefits of the PBS to the Australian community and the impact of increased copayments', Health Issues, no. 71, pp. 1-8.
13. Gupta, A. and Kapur, V. (eds) 2000, Microsimulation in Government Policy and Forecasting, Contributions to Economic Analysis Series, North Holland, Amsterdam.
14. Harding, A. 1995, 'The social wage and income distribution: The impact of health, education and housing outlays in 1994', Australian Economic Review, 3rd quarter, pp. 71-86.
15. Harding, A. (ed.) 1996, Microsimulation and Public Policy, Contributions to Economic Analysis Series, North Holland, Amsterdam.
16. Harding, A., Percival, R., Schofield, D. and Walker, A. 2002, 'The lifetime distributional impact of government health outlays', Australian Economic Review, vol. 35, pp. 363-79.
17. Harvey, K. 2002, 'Securing the future of the Pharmaceutical Benefits Scheme?', Drawing Board: An Australian Review of Public Affairs, 3 June, .
18. Hill, S. R., Mitchell, A. S. and Henry, D. A. 2000, 'Problems with the interpretation of pharmacoeconomic analyses: A review of submissions to the Australian Pharmaceutical Benefits Scheme', JAMA, vol. 283, pp. 2116-21.
19. Horn, S. D. 2002, 'Implications of restrictive drug practices', Working Paper, Institute for Clinical Outcomes Research, Salt Lake City, Utah.
20. Horn, S. D., Sharkey, P. D., Kelly, H. W. and Uden, D. L. 2001, 'Newness of drugs and use of HMO services by asthma patients', Annals of Pharmacotherapy, vol. 35, pp. 990-6.
21. Johnson, D., Manning, I. and Hellwig, O. 1995, Trends in the Distribution of Cash Income and Non Cash Benefits: An Overview, Report to the Department of the Prime Minister and Cabinet, AGPS, Canberra.
22. Lichtenberg, F. R. 1996, 'The effect of pharmaceutical utilization and innovation on hospitalisation and mortality', Working Paper 5418, National Bureau of Economic Research, Cambridge.
23. Lichtenberg, F. R. 1998, 'Pharmaceutical innovation, mortality reduction, and economic growth', Working Paper 6569, National Bureau of Economic Research, Cambridge.
24. Lichtenberg, F. R. 1999, 'Pharmaceutical innovation, mortality reduction, and economic growth', paper presented to Economic Value of Medical Research Conference, Washington.
25. Lichtenberg, F. R. 2001, 'Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS', Health Affairs, vol. 20, no. 5, pp. 241-51.
26. Lichtenberg, F. R. 2002a, 'Benefits and costs of newer drugs: An update', Working Paper 8996, National Bureau of Economic Research, Cambridge.
27. Lichtenberg, F. R. 2002b, 'The economic benefits of new drugs', Economic Realities in Health Care Policy, vol. 2, no. 2, pp. 14-19.
28. Lichtenberg, F. R. 2002c, 'The effect of changes in drug utilization on labor supply and per capita output', Working Paper 9139, National Bureau of Economic Research, Cambridge.
29. Lichtenberg, F. R. and Virabhak, S. 2002, 'Pharmaceutical embodied technical progress, longevity, and quality of life: Drugs as "equipment for your health"', Working Paper 9351, National Bureau of Economic Research, Cambridge.
30. Lofgren, H. 2001, 'Pharmaceutical benefits in Australia and welfare policy and the cost of prescription drugs', Australian Journal of Social Issues, vol. 36, pp. 207-20.
31. Merz, J. 1991, 'Microsimulation-A survey of principles, developments and applications', International Journal of Forecasting, vol. 7, pp. 77-104.
32. Merz, J. 1994, 'Microsimulation-A survey of methods and applications for analyzing economic and social policy', Discussion Paper no. 9, Forschungsinstitut Freie Berufe, Universitat Luneburg.
33. Orcutt, G. 1957, 'A new type of socio-economic system', Review of Economics and Statistics, vol. 58, pp. 773-97.
34. Orcutt, G., Greenberger, M., Korbel, J. and Rivlin, A. 1961, Microanalytic Simulation Models to Support Social and Financial Policy, Harper and Row, New York.
35. Percival, R. and Schofield, D. 1995, 'Modelling Australian public health expenditure', STINMOD Technical Paper no. 8, National Centre for Social and Economic Modelling, University of Canberra.
36. Productivity Commission 2001, International Pharmaceutical Price Differences: Research Report, AusInfo, Canberra.
37. Rickard, M. 2002, 'The Pharmaceutical Benefits Scheme: Options for cost control', Current Issues Brief, no. 12 2001-02, Department of the Parliamentary Library.
38. Sansom, L. 2001, 'The PBS-Its future', Australian Journal of Hospital Pharmacy, vol. 31, p. 257.
39. Schofield, D. 1998, 'Re-examining the distribution of health benefits in Australia: Who benefits from the Pharmaceutical Benefits Scheme?', Discussion Paper no. 36, National Centre for Social and Economic Modelling, University of Canberra.
40. Schofield, D. 1999, 'Modelling health care expenditure: A new microsimulation approach to simulating the distributional impact of the Pharmaceutical Benefits Scheme', PhD in Information Sciences and Engineering, University of Canberra.
41. van Hout, B., Bonsel, G., Habbema, D., van der Maas, P. and de Charro, F. 1993, 'Heart transplantation in the Netherlands: Costs, effects and scenarios', Journal of Health Economics, vol. 12, pp. 73-93.
42. Walker, A. 2000, 'Distributional impact of higher patient contributions to Australia's Pharmaceutical Benefits Scheme', Australian Health Review, vol. 23, no. 2, pp. 32-46.
43. Walker, A., Percival, P. and Fischer, S. 1998, 'A microsimulation model of Australia's Pharmaceutical Benefits Scheme', Technical Paper no. 15, National Centre for Social and Economic Modelling, University of Canberra.
44. Walker, A., Percival, P. and Harding, A. 2000, 'The impact of demographic and other changes on expenditure on pharmaceutical benefits in 2020 in Australia', in Microsimulation Modelling for Policy Analysis: Challenges and Innovations, eds L. Mitton, H. Sutherland and M. Weeks, Cambridge University Press, United Kingdom.